- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04468373
Study of WA-NG (NG-IMT) Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
Study of the WA-NG (NG-IMT) Telescope Prosthesis in Patients With Central Vision Impairment Associated With End-Stage Age Related Macular Degeneration
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will be screened for eligibility and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. Eligible patients will be examined preoperatively to obtain a medical history and to establish a baseline for ocular condition.
Postoperatively, patients will undergo ophthalmic evaluation at regular intervals as specified in this protocol.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
**The following Inc. & Exc. are sample and not completed list **
Main Exclusion Criteria:
- Patients with bilateral, stable, moderate to profound central vision impairment due to bilateral central scotoma associated with end-stage macular degeneration, defined as retinal findings of bilateral, geographic atrophy or disciform scar with foveal involvement.
- Patients must have distance BCVA between 20/80 and 20/800, and adequate peripheral vision in one eye (the non-implanted eye) to allow navigation
- Patients must achieve at least a five letter improvement on the ETDRS chart in the eye scheduled for surgery, with the external telescope simulator (ETS)
- Patients must be available for the study duration of 12 months
- Patients must be alert, mentally competent, and able to understand and comply with the requirements of the clinical trial, and be personally motivated to abide by the requirements and restrictions of the clinical trial.
Main Exclusion Criteria:
- Evidence of active CNV on fluorescein angiography or treatment for CNV within the past six months.
- Patients who may require fellow eye cataract extraction and intraocular lens implantation during the 12 months following WA-NG telescope implantation. If fellow eye cataract extraction is anticipated, this procedure should be performed at least 30 days prior to enrollment in the clinical study.
- Patients who have had or are expected to have ophthalmic related surgery within the 30 days preceding implantation of the device.
- Patients who have undergone previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes.
- Patients participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: WA-NG (NG-IMT) Telescope Prothesis
Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
|
The WA-NG telescope prosthesis is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration.
The device is implanted in one of the patient's eyes.
In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positional stabilitytilt (the following parameter will be measured/ assessed :device centered (yes/ no) questionnaire)
Time Frame: 12 months
|
Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam) and anterior segment Ocular Coherence Tomography (OCT is a non-invasive imaging test )
|
12 months
|
Positional stabilitytilt, the following parameter will be measured/ assessed : tilted (° C)
Time Frame: 12 months
|
Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam) and anterior segment Ocular Coherence Tomography (OCT is a non-invasive imaging test )
|
12 months
|
Positional stabilitytilt , the following parameter will be measured/ assessed : malpositioned (yes/no) questionnaire
Time Frame: 12 months
|
Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam) and anterior segment Ocular Coherence Tomography (OCT is a non-invasive imaging test )
|
12 months
|
Positional stabilitytilt , the following parameter will be measured/ assessed : endothelial cell count (Cells/mm2))
Time Frame: 12 months
|
12 months
|
|
Positional stabilitytilt , the following parameter will be measured/ assessed : Intraocular pressure (mmHg)
Time Frame: 12 months
|
Device positional stability will be assessed by slit lamp examination (microscope with a bright light used during an eye exam)
|
12 months
|
Number of Adverse events associated with the implant and use of the device will be evaluated.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Diane Gordon, VisionCare Ophthalmic Technologies
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WA-NG-001 EUROPE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitationExudative Age-Related Macular DegenerationChina
Clinical Trials on WA-NG (NG-IMT) Telescope Prothesis
-
VisionCare, Inc.WithdrawnAge Related Macular DegenerationIsrael
-
VisionCare, Inc.WithdrawnAge Related Macular DegenerationIsrael
-
VisionCare, Inc.RecruitingAge-Related Macular Degeneration | AMDItaly, Ireland, Spain, Germany, United Kingdom